(Total Views: 141)
Posted On: 09/13/2022 6:20:17 AM
Post# of 25492
Regencell Bioscience Holdings Limited (RGC), a Hong Kong, China-based company, is focused on developing traditional Chinese medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder.
RGC made its debut on the Nasdaq Capital Market on July 16, offering its shares at a price of $9.50 each. The stock, which opened at $12 that day, recorded a high of $59 on Aug.25, and that reflects a gain of 521% over the offer price.
In the company's first study using personalized traditional Chinese medicine formula in Hong Kong, there was a drop in assessment scores meaning that Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder symptoms were less severe for patients who participated in the study.
RGC has thus far hit a low of $6.00 and a high of $59.00. The stock closed Friday's trading at $33.79
According to stockanalysis.com/ipos/2021/, Regencell Bioscience ($RGC) is now the best-performing stock of all 2021 IPOs. RGC is still rated first as of September 11, 2022, having gained around 200 percent more than its $9.50 IPO price.
https://www.nasdaq.com/articles/top-biotech-i...uch-as-500
RGC made its debut on the Nasdaq Capital Market on July 16, offering its shares at a price of $9.50 each. The stock, which opened at $12 that day, recorded a high of $59 on Aug.25, and that reflects a gain of 521% over the offer price.
In the company's first study using personalized traditional Chinese medicine formula in Hong Kong, there was a drop in assessment scores meaning that Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder symptoms were less severe for patients who participated in the study.
RGC has thus far hit a low of $6.00 and a high of $59.00. The stock closed Friday's trading at $33.79
According to stockanalysis.com/ipos/2021/, Regencell Bioscience ($RGC) is now the best-performing stock of all 2021 IPOs. RGC is still rated first as of September 11, 2022, having gained around 200 percent more than its $9.50 IPO price.
https://www.nasdaq.com/articles/top-biotech-i...uch-as-500
(0)
(0)
